DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Contract/Agreement 
Eckert & Ziegler Granted Exclusive Distribution Rights by Telix Pharmaceuticals for Prostate Cancer Diagnostic 
2021-05-18 / 09:14 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Berlin, 18.05.2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed an agreement with Telix Pharmaceuticals 
(Telix), an Australian-headquartered company, for the exclusive distribution of Illuccix^(R) (Kit for the preparation 
of Ga-68 PSMA-11 injection) in Germany. Illuccix^(R) is a preparation for imaging prostate cancer with positron 
emission tomography (PET), currently under review for regulatory approval in multiple markets worldwide, including 
Germany. 
"Illuccix^(R) is anticipated to be one of the most important imaging products for prostate cancer. Widespread approval 
of a preparation for the diagnosis of prostate cancer is urgently needed and we are pleased to have Telix, a pioneer in 
bringing this drug to market, as a partner," explained Dr Harald Hasselmann, member of the Executive Board of Eckert & 
Ziegler AG and responsible for the Medical segment. "Together with our other products, we will be able to offer nuclear 
medicine practices and clinics in Germany a fully comprehensive product portfolio for the production of Ga-68 PSMA, 
once approval has been attained." 
"We are pleased to have entered this commercial distribution agreement with Eckert & Ziegler so that, subject to German 
regulatory approval, we will together be able to deliver a commercial product to German patients living with prostate 
cancer as efficiently as possible. Partnering with such a capable and patient-centric leader in nuclear medicine 
uniquely aligns with Telix's mission of helping patients with cancer live longer, better quality lives", explained 
Telix Chief Executive Officer Dr Christian Behrenbruch. 
Illuccix^(R) is offered as a so-called kit preparation for the diagnosis of prostate cancer. For this purpose, Illuccix 
^(R) enables PSMA-11 to be labelled with the radionuclide Ga-68 directly before injection by medical personnel. After 
preparing the radiopharmaceutical and injecting it into the patient, tumours that show the so-called prostate-specific 
membrane antigen can be localised by PET.^[1],[2] 
Prostate cancer is the most common type of cancer in men in Germany, with approximately 68,000 cases in 2020, a 
significantly higher incidence than either lung cancer (38,000 new cases) or bowel cancer (31,000 new cases).^[3] 
Prostate cancer was also the second most common cause of cancer death in men, with over 15,000 men dying from the 
disease in Germany in 2020. More than 290,000 German men were estimated to be living with prostate cancer in 2020. 
^[1] Fendler W et al. JAMA Oncol. 2019; 5(6): 856-863. 
^[2] Hofman M et al. The Lancet. 2020; 395: 1208-1216. 
^[3] IARC Global Cancer Observatory, 2020. 
About Eckert & Ziegler. 
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers 
of isotope-related components for nuclear medicine and radiation therapy. The company offers services for 
radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares 
(ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. 
Contributing to saving lives. 
About Telix Pharmaceuticals 
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products 
using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international 
operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that 
address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities 
Exchange (ASX: TLX). For more information visit www.telixpharma.com 
About Illuccix^(R) 
Telix's lead investigational product, Illuccix^(R) (TLX591-CDx) for prostate cancer imaging, has been accepted for 
filing by the U.S. FDA, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA). 
Telix is also progressing marketing authorisation applications for Illuccix^(R) in the European Union and Canada. None 
of Telix's products have received a marketing authorisation in any jurisdiction. 
Eckert & Ziegler AG Contact: 
Karolin Riehle, Investor Relations 
Robert-Rössle-Str. 10, 13125 Berlin, Germany 
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 
Telix Pharmaceuticals Contact: 
Dr. Stewart Holmstrom, Investor Relations 
Suite 401, 55 Flemington Road, North Melbourne, VIC 3051, Australia 
Email: stewart.holmstrom@telixpharma.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-05-18 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Eckert & Ziegler Strahlen- und Medizintechnik AG 
              Robert-Rössle-Str.10 
              13125 Berlin 
              Germany 
Phone:        +49 30 941084-138 
Fax:          +49 30 941084-112 
E-mail:       karolin.riehle@ezag.de 
Internet:     www.ezag.de 
ISIN:         DE0005659700 
WKN:          565970 
Indices:      SDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1197562 
 
End of News   DGAP News Service 
=------------ 

1197562 2021-05-18


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1197562&application_name=news

(END) Dow Jones Newswires

May 18, 2021 03:15 ET (07:15 GMT)